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Macrophages orchestrate an inflammatory response that contributes to glucose intolerance in diet-
induced obesity and plaque instability in atherosclerosis. Within this heterogeneous group of cells
are proinflammatory (M1) and anti-inflammatory (M2) macrophages. Recent work has identified the
nuclear hormone receptor PPARg as a critical signalingmolecule in determiningmacrophage pheno-
type in vitro and in adipose tissue. In the current issue ofCell Metabolism, Bouhlel et al. (2007) extend
this paradigm to the vessel wall by showing that both M1 and M2 macrophages are present in ath-
erosclerotic lesions and that activation of PPARg polarizes circulating blood monocytes to become
M2 macrophages.The past decade has witnessed an impressive increase
in our appreciation of the importance of inflammation in
atherosclerosis, with much attention focused on the role
of macrophages within lipid-rich plaques (Hansson and
Libby, 2006). The convergence of several lines of evidence
now suggests that inflammation is also a critical compo-
nent in the pathogenesis of insulin resistance and the
metabolic syndrome (Shoelson et al., 2006). Recent pub-
lications have shown that macrophages are recruited to
adipose tissue (Weisberg et al., 2003; Xu et al., 2003),
that adipose-tissue macrophages (ATMs) regulate insulin
sensitivity (Xu et al., 2003), and that the nuclear hormone
receptor peroxisome proliferator-activated receptor g
(PPARg) is a central switch that regulates the inflammatory
potential of macrophages in both adipose tissue and
atherosclerotic plaques (Hevener et al., 2007; Odegaard
et al., 2007). These findings indicate that important
aspects of the metabolic syndrome and atherosclerosis
have common underpinnings in macrophage-mediated
inflammation.
The earliest pathologic manifestation of atherosclerosis
is the ‘‘fatty streak,’’ which is composed of lipid-laden
macrophages known as foam cells. The precursors of
foam cells are circulating blood monocytes that are re-
cruited to the vessel wall by chemokines. The chemokine
monocyte chemoattractant protein 1 (MCP-1, also known
as chemokine ligand 2 or CCL2) is upregulated in athero-
sclerotic plaques and recruits monocytes that express the
cognate receptor, chemokine receptor 2 (CCR2), to devel-
oping lesions (Boring et al., 1998; Gu et al., 1998). The net
effect of macrophage infiltration into tissues is always
dependent upon a delicate balance between positive, re-
parative functions and negative, proinflammatory effects.
In atherosclerosis, macrophages are likely recruited to
early plaques to phagocytose oxidized lipids and apopto-
tic cells. However, within the vessel wall, macrophages
contribute to lesion growth and plaque rupture by secret-
ing growth factors and proteolytic enzymes.96 Cell Metabolism 6, August 2007 ª2007 Elsevier Inc.It has been difficult to distinguish the ‘‘good’’ and ‘‘bad’’
macrophages in plaques and to identify molecular mech-
anisms that control their conversion from one state to the
other. In the current issue ofCell Metabolism, Bouhlel et al.
(2007) show that human endarterectomy specimens con-
tain both classically activated proinflammatoryM1macro-
phages and anti-inflammatory/reparative M2 macro-
phages that are derived from monocytes activated along
the alternative pathway (Gordon, 2003). They demonstrate
that the expression of PPARg in these vessels colocalizes
with CD68-positive macrophages and that incubation of
M1 macrophages with supernatant from cultures of M2
macrophages inhibits the secretion of proinflammatory
mediators. Interestingly, PPARg-dependent polarization
to the M2 phenotype appeared to occur at the level of the
monocyte, because in vivo administration of a thiazolidine-
dione (TZD) upregulated M2 markers in monocytes, but
not in vessel-wall macrophages. These results are consis-
tent with earlier work demonstrating that activation of
macrophage PPARg inhibits the expression of a wide
range of inflammatory mediators (Ricote et al., 1998) and
suggest a dynamic balance in which PPARg controls the
inflammatory potential of the macrophage both in athero-
sclerotic plaques and in adipose tissue.
Insulin resistance is associated with the metabolic syn-
drome, a constellation of symptoms including obesity,
glucose intolerance, and dyslipidemia that has reached
epidemic proportions in the Western world. In mice, diet-
induced obesity leads to macrophage recruitment to white
adipose tissueandan increase in thepresenceof inflamma-
torymediators, such as tumor necrosis factor a (TNF-a), in-
terleukin-6 (IL-6), and MCP-1 (Weisberg et al., 2003). Mice
genetically deficient in CCR2 accumulate fewer macro-
phages in adipose tissue in response to a high-fat diet and,
significantly, have improved insulin resistance (Weisberg
et al., 2006). These studies reveal mechanistic parallels be-
tween CCR2-dependent recruitment of monocyte/macro-
phages to adipose tissue and atherosclerotic plaques.
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Atherosclerotic plaques and white adipose
tissue contain both M1 (proinflammatory) and
M2 (anti-inflammatory) macrophages. Circu-
lating blood monocytes are the precursors of
these macrophages, and activation of PPARg
polarizes monocyte/macrophages to the M2
phenotype. The chemokine receptor CX3CR1
is upregulated by PPARg activation, while
CCR2 is downregulated, though it is not clear
that CX3CR1 and CCR2 recruit only M2 and
M1 macrophages, respectively.Evidence that the macrophage phenotype is modulated
by adipose tissue was provided by Lumeng et al., (2007),
who compared ATMs in lean and obese mice. They found
a phenotypic switch from M2 macrophages in lean mice
to M1 macrophages in mice with diet-induced obesity.
Obesity thus led to a change in the polarization of ATMs
to a state that favors inflammation and insulin resistance.
Interestingly, ccr2/ATMswere polarized to theM2 type,
even when the mice were fed a high-fat diet. These results
are consistent with the observation that ccr2/ mice are
protected from diet-induced insulin resistance (Weisberg
et al., 2006) and raise the question of whether CCR2 acti-
vation is necessary for monocytes to differentiate into
proinflammatory macrophages. Bouhlel and colleagues
(2007) now extend this paradigm to the vessel wall by
showing that M2 and M1 macrophages are present in
human atherosclerotic lesions.
Insights into the mechanism of macrophage-mediated
insulin resistance can be found in work by Arkan et al.
(2005), who reported attenuation of diet-induced insulin
resistance inmicewith amyeloid-specific targeted disrup-
tion of IKKb, a key regulator of NF-kB activity. Administra-
tion of high-dose salicylates, which are thought to inhibit
NF-kB, also improves glucose homeostasis in insulin-
resistant rodents (Yuan et al., 2001). Evidence for the cen-
tral role ofmacrophages in insulin resistance is providedby
recent studies demonstrating that deletion of PPARg pre-
vents polarization of monocyte/macrophages to the M2
phenotypeand impairs insulinaction. Inmicewithamacro-
phage-specific deletion of PPARg, Odegaard et al. (2007)
found impairment in the maturation of alternatively acti-
vated M2 macrophages and exacerbation of diet-induced
obesity, insulin resistance, and glucose intolerance.
Hevener et al. (2007) found selective inactivation of PPARg
in macrophages in C57BL/6J mice resulted in glucose in-
tolerance, insulin resistance in skeletal muscle and liver,
and increased expression of inflammatory mediators inthese tissues. The effects were exacerbated by a high-fat
diet and were only partially reversed by administration
of a TZD. These findings demonstrate that macrophage
PPARg is a significant target of TZDs and that activation
of PPARg inmacrophages has systemic anti-inflammatory
effects and improves insulin sensitivity in tissues that are
not rich in macrophages. Together, these results provide
evidence that macrophage PPARg is a critical regulator
of inflammation and insulin resistance.
A number of questions surrounding the role of PPARg in
monocyte/macrophage polarization remain unanswered.
First, although the work of Bouhlel et al. (2007) suggests
that PPARg-dependent M2 polarization occurs in circulat-
ing monocytes, it is not clear whether the local cytokine
environment in adipose tissue or fatty-streak lesions also
regulates macrophage polarization, particularly to the in-
flammatoryM1 phenotype. If polarization is predominately
a monocyte phenomenon, are M1 and M2 monocytes
recruited equally well to adipose tissue and vascular le-
sions? It is interesting, in this regard, that activation of
PPARg by oxidized lipids downregulates monocyte CCR2
(Han et al., 2000) while upregulating CX3CR1 (Barlic et al.,
2006), the chemokine receptor for fractalkine (Figure 1).
Whether CX3CR1 plays a significant role in the preferential
recruitment of M2 monocyte/macrophages to atheroscle-
rotic lesions is not known. Finally, the endogenous PPARg
ligand or ligands that polarize monocyte/macrophages
in vivo are not known.
The finding that activation of macrophage PPARg by
TZDs improves insulin sensitivity and increases the pro-
portion of M2 macrophages in adipose tissue and athero-
sclerotic lesions, combined with extensive data in mice
demonstrating that PPARg activation reduces inflamma-
tion and decreases atherosclerotic lesion size, would
seem to recommend TZDs as promising cardiovascular
therapeutics. In particular, patients with the metabolic
syndrome and type 2 diabetes, in whom acceleratedCell Metabolism 6, August 2007 ª2007 Elsevier Inc. 97
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cause of mortality, might be expected to realize the most
benefit from a TZD. In practice, however, TZDs have had
mixed effects on cardiovascular endpoints. A recent
meta-analysis of 42 studies of patients treated with rosigli-
tazone revealed a significant increase in the odds ratio for
both myocardial infarction and death from cardiovascular
events (Nissen and Wolski, 2007). Although the mecha-
nisms for these events are not clear, activation of PPARg
by TZDs induces transcription of dozens of genes and
causes untoward effects such as weight gain, increase
in low-density lipoprotein cholesterol, and expansion of
plasma volume (Spiegelman, 1998).
Although TZDs have both positive (i.e., transcription-
activating) and negative (i.e., anti-inflammatory) effects,
it is worth noting that they were discovered and optimized
for their ability to control blood glucose levels, and not for
their anti-inflammatory effects. From the point of view of
converting macrophages in adipose tissue or atheroscle-
rotic plaques from an M1 to an M2 phenotype, however, it
is the anti-inflammatory effects of PPARg activation that
one would like to optimize. It is encouraging that Pascual
et al. (2005) have identified a novel pathway whereby ac-
tivation of macrophage PPARg represses the expression
of a number of NF-kB-dependent inflammatory genes.
The mechanism of transrepression of these genes is dis-
tinct from PPARg-dependent activation of transcription,
which, as noted above, can be associated with undesir-
able cardiovascular side effects. This finding raises the
intriguing possibility that small molecules might be found
that promote the anti-inflammatory properties of PPARg
and perhaps its insulin-sensitizing properties as well, with-
out the untoward side effects associated with transcrip-
tional activation. However, TZDs and other PPARg ligands
inhibit the secretion of TNF-a and IL-6 in PPARg-deficient
macrophages (Chawla et al., 2001a), indicating that at
least a portion of their anti-inflammatory effect is PPARg
independent. It remains to be determined whether a drug
that represses inflammatory gene expression, without
activating transcription, would be efficacious in the treat-
ment of atherosclerosis or insulin resistance.
In summary, several lines of evidence support a central
role for macrophage-mediated inflammation in the patho-
genesis of atherosclerosis and insulin resistance. Macro-
phage infiltration is a prominent feature of both diseases,
and both proinflammatory M1 macrophages and anti-
inflammatoryM2macrophages are present in fatty streaks
and adipose tissue. The relative abundance of these two
types ofmacrophagesmaychangedynamically by recruit-
ment of polarizedmonocytes from theblood or through the
effects of local cytokines on macrophages in the tissues.
Activation of PPARg is critically involved in macrophage
polarization to the M2 phenotype in both adipose tissue
and atherosclerotic lesions and improves insulin sensitiv-
ity. Conversely, selective deletion of PPARg in macro-
phages increases insulin resistance and exacerbates ath-
erosclerosis (Chawla et al., 2001b; Babaev et al., 2005).
These studies provide evidence that PPARg is a critical98 Cell Metabolism 6, August 2007 ª2007 Elsevier Inc.regulator of the inflammatory potential of tissue macro-
phages and identify it as a potential therapeutic target for
the treatment of both themetabolic syndrome and athero-
sclerosis.
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